Drug name - Rhofade

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815929 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists Jan, 2024

(1 year, 3 months from now)

US8420688 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists Aug, 2024

(1 year, 9 months from now)

US7812049 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists May, 2028

(5 years from now)

US8883838 EPI HLTH Pharmaceutical cream compositions and methods of use Dec, 2031

(9 years from now)

US10751325 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

US9974773 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

US10335391 EPI HLTH Stabilized oxymetazoline formulations and their uses Jun, 2035

(12 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.